Analysis of non‐responders to dupilumab in clinical practice: a cohort study

Linder, C.; Shourick, Jason; Touhouche, A.T.; Giordano‐Labadie, F.; Sévérino-Freire, Maëlla; Börjesson, Camilla; Richet, C.; Marguery, M.C.; Tauber, M.; Paul, C.

doi:10.1111/jdv.16900

Cited by 4 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 19 Although recent treatments such as dupilumab have been a turning point for many patients, there are still a subset of patients who are partial or complete nonresponders. 21 , 22 Although it is unclear why some patients do not respond, it may be due in part to their subtype of AD. Though, 1 open-label Italian observational study of 221 patients treated with dupilumab found that it was effective across multiple AD phenotypes, including nummular eczema, prurigo, and erythroderma.…”

Section: Resultsmentioning

confidence: 99%

Phenotypic differences of atopic dermatitis stratified by age

Iyer

Silverberg

2023

JAAD International

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Phenotypic differences of atopic dermatitis stratified by age

Iyer

Silverberg

2023

JAAD International

View full text Add to dashboard Cite

“…Ferrucci et al [ 19 ] reported that the predictors of patients who achieved EASI-75 after 4 weeks of treatment were early AD onset and the absence of hypereosinophilia (>500 × 10 3 /L), while no predictors achieved EASI-75 after 16 weeks of treatment. Linder et al [ 20 ] defined patients who achieved a SCORing Atopic Dermatitis (SCORAD) score of 75 after 16 weeks as optimal responders, and their predictors were lower weight and less frequent exposure to tobacco and alcohol. Olesen et al [ 21 ] found that the predictors of patients who achieved EASI-75 were female sex, lower age, lower baseline EASI, and lower baseline IgE after 4 weeks of treatment, and only female patients after 12 weeks.…”

Section: Discussionmentioning

confidence: 99%

Exploration of Metabolite Biomarkers to Predict the Efficacy of Dupilumab Treatment for Atopic Dermatitis

Miyamoto,

Imai,

Matsutani

et al. 2023

Disease Markers

View full text Add to dashboard Cite

Dupilumab (DUP) is the first biological agent used treating atopic dermatitis (AD). Notwithstanding its high cost, the type of patient group for which the drug is effective remains unclear. In this retrospective study, we aimed to identify novel and reliable biomarkers which can be measured before DUP administration and to predict the efficacy of DUP. Serum samples from 19 patients with AD treated with DUP were analysed by metabolome analysis using gas chromatography–mass spectrometry. Total 148 metabolites were detected, and the relative values of the metabolites were compared between the patient group that achieved 75% improvement in Eczema Area and Severity Index 16 weeks after administration of DUP (high responders: HR; n = 11) and that did not (low responders: LR; n = 8). The HR and LR groups had significant differences in the relative values of the eight metabolites (lactic acid, alanine, glyceric acid, fumaric acid, nonanoic acid, ribose, sorbitol, and ornithine), with ribose emerging as the best. Furthermore, we evaluated the serum concentrations of ribose and found that ribose may be a useful metabolite biomarker for predicting the efficacy of DUP in AD.

show abstract

“…4 However, despite dupilumab’s superior efficacy over prior treatments, nonresponse to dupilumab is not infrequent. 4 In a cohort study of 96 adults with moderate-to-severe AD, treated with dupilumab, 42.5% were nonresponsive, defined as failure to reach a 50% improvement after 4 months of treatment. 4 Options for patients who are nonresponsive to dupilumab are limited and there is a need for other effective treatments in this subset of patients.…”

Section: Introductionmentioning

confidence: 99%

“…4 In a cohort study of 96 adults with moderate-to-severe AD, treated with dupilumab, 42.5% were nonresponsive, defined as failure to reach a 50% improvement after 4 months of treatment. 4 Options for patients who are nonresponsive to dupilumab are limited and there is a need for other effective treatments in this subset of patients. 5 Other unmet needs in the management of AD include medications for patients who lose treatment response, have contraindications to conventional systemic treatments or biologics, or who prefer an oral medication.…”

Section: Introductionmentioning

confidence: 99%

“…3 The biologic, dupilumab, an IL-4 and IL-13 inhibitor, has revolutionized the management of patients with moderate-to-severe AD. 4 However, despite dupilumab's superior efficacy over prior treatments, nonresponse to dupilumab is not infrequent. 4 In a cohort study of 96 adults with moderate-to-severe AD, treated with dupilumab, 42.5% were nonresponsive, defined as failure to reach a 50% improvement after 4 months of treatment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis

2022

View full text Add to dashboard Cite

Objective The objective of this article is to review abrocitinib, an oral Janus kinase (JAK) 1 inhibitor, for the treatment of patients with moderate-to-severe atopic dermatitis (AD). Data Sources A literature search of MEDLINE (PubMed) was performed for articles from inception through end-March 2022 using the following search terms: atopic dermatitis, abrocitinib, PF-04965842, methotrexate, cyclosporine, dupilumab, ruxolitinib, and JAK-STAT pathway. Study Selection and Data Extraction English articles relating to pharmacology, pharmacokinetics, efficacy, and safety of abrocitinib, and other conventional systemic medications for AD, were included. Data Synthesis Across phase IIb and phase III clinical trials, abrocitinib was efficacious with an average of 47.5% patients on 200 mg abrocitinib and 32.0% on 100 mg abrocitinib achieving an Investigator’s Global Assessment (IGA) of 0 or 1 at 12 weeks. In comparison with dupilumab 300 mg subcutaneously every other week, patients on abrocitinib 200 mg once daily had improved disease severity and itch response. The majority of adverse events were not severe and self-limited. Relevance to Patient Care and Clinical Practice Prior to Food and Drug Administration (FDA) approval of abrocitinib, prednisone was the only FDA-approved oral medication for AD. Although biologics such as dupilumab have revolutionized care, some patients prefer oral medications. Compared with clinical trials of conventional AD treatments, abrocitinib appears more effective. Conclusions Abrocitinib is an efficacious oral JAK 1 inhibitor recently FDA-approved for patients ≥ 18 years old with moderate-to-severe AD who have not responded to systemic medications or when contraindicated otherwise.

show abstract

Analysis of non‐responders to dupilumab in clinical practice: a cohort study

Cited by 4 publications

References 10 publications

Phenotypic differences of atopic dermatitis stratified by age

Phenotypic differences of atopic dermatitis stratified by age

Exploration of Metabolite Biomarkers to Predict the Efficacy of Dupilumab Treatment for Atopic Dermatitis

Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis

Contact Info

Product

Resources

About